Welcome to ENLIGHTEnMENT, where we are dedicated to advancing research on light chain amyloidosis and its cardiotoxicity. One of the ways we achieve this is through organising a variety of engaging events for both the scientific community and the general public.

• 38th Meeting of the European Section of the ISHR, June 2024, Toulouse, France.

Poster presention: Cardiotoxicity in light chain amyloidosis: establishment of animal models with acute and chronic induced cardiotoxicity from patient-derived amyloidogenic light chains

• Meeting of the International Society of Amyloidosis, May 2024, Mayo clinic, Rochester Minesota, USA.

Poster presention. Cardiotoxicity in light chain amyloidosis: Insights from the first murine model with intramyocardial injection of patient-derived amyloidogenic light chains. 

• 2^nd Panhellenic congress I.E.M.BI.ΘΕ.Κ: Amyloidosis and other Rare Hematologic Neoplasms: Approaches to Diagnosis and Treatment, February 2024, Athens, Greece.

Invited speach: Light chain and transthyretin associated induced cardiotoxicity.

• Biennial meeting: Cellular Biology of the Heart & Myocardial Function Meeting, November 2023, Naples – Italy.    

 Best poster award:  In vitro and in vivo characterization of cardiotoxicity in light chain amyloidosis. 

• European Society of Cardiology congress, August 2023, Amsterdam, The Nederlands.

 Moderated Poster presention: Cardiotoxicity in light chain amyloidosis: Insights from the first murine model with intramyocardial injection of patient-derived amyloidogenic light chains.

• Conference of the Hellenic Society of Pharmacology, May 2023, Athens, Greece: Poster: Cardiotoxicity in light chain amyloidosis: Insights from the first murine model with intramyocardial injection of patient-derived amyloidogenic light chains
• 1^st Panhellenic congress I.E.M.BI.ΘΕ.Κ: Amyloidosis and other Rare Hematologic Neoplasms: Approaches to Diagnosis and Treatment, February 2023, Athens, Greece.

Invited speach: Light chain induced cardiotoxicity.

• 33^rd Panhellenic congress of Hematology, November 2022, Thessaloniki, Greece.

Abstract presention: Light chain amyloidosis and cardiac involvement: Investigation of the light chain induced cardiotoxicity in vitro and in vivo.

• 12^th Congress of the Hellenic Society of Basic and Clinical Pharmacology, October 2022, Arta, Greece.

Best poster award: Cardiotoxicity in cardiac light chain amyloidosis: implication and therapeutic potential of endoplasmic reticulum stress.

• Meeting of the International Society of Amyloidosis, September 2022, Heidelberg, Germany.

Abstract presention: Elucidation of the cardiotoxicity of full-length light chains derived from patients with cardiac light chain amyloidosis in comparison to other plasma cell dyscrasias.

• European Society of Cardiology congress, August 2022, Barcelona, Spain.

Moderated Poster presention: Understanding the molecular mosaic of cardiotoxicity of light chains in plasma cell dyscrasias and cardiac light chain amyloidosis with the use of patient derived full-length light chains.

• XXIV World Congress of International Society for Heart Research June 2022, Berlin, Germany.

Poster Presention: Investigation of the cardiotoxicity of full-length light chains derived from patients with plasma cell dyscrasias and cardiac light chain amyloidosis. 

• Congress of Rare plasma cell dyscrasias: The state of the art, February 2022.

Invited speach: Amyloid typing with mass spectrometry.